United States:
Podcast: Onshoring Drug Manufacturing And TRIPS Waiver Part II
23 September 2021
Akin Gump Strauss Hauer & Feld LLP
To print this article, all you need is to be registered or login on Mondaq.com.
Subscribe to OnAir with Akin
Gump via iTunes, SoundCloud, YouTube, Spotify and
Google Play.
In this new episode of OnAir: Health Care, Akin
Gump health care senior policy advisor Matthew Hittle and consultant Dr. Mario Ramirez welcome Akin Gump
public law and policy partner Clete Willems and Centrient
Pharmaceuticals chief legal and compliance officer Jim
DeYonker.
Among the topics covered:
- The TRIPS waiver and vaccines.
- Global supply chains.
- Onshoring drug manufacturing.
- Enforcing IP outside the U.S..
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Food, Drugs, Healthcare, Life Sciences from United States
Healthcare Policy Developments To Watch In 2024
Crowell & Moring LLP
The ever-changing healthcare policy landscape will witness at the federal level regulatory changes driven by the need to transform healthcare delivery, quality and innovation.
The FDA And The Future Of AI Oversight
Manatt, Phelps & Phillips LLP
In January 2024, the U.S. Government Accountability Office (GAO) issued a report highlighting current obstacles to the U.S. Food and Drug Administration's (FDA) timely and effective regulation...